Homologous recombination deficiency (HRD) is an important biomarker of poly (ADP-ribose) polymerase inhibitor (PARPi) in patients with high-grade serous ovarian cancer (HGSOC). The stability of HRD in the recurrent HGSOC and its primary pair remains unknown.
This study intends to perform HRD testing of ovarian cancer in the recurrent HGSOC and its primary pair, furtherly correlate HRD status and clinical characteristics in the recurited population.
Study Type
OBSERVATIONAL
Enrollment
50
Xiaoxiang Chen
Nanjing, Jiangsu, China
Loss of heterozygosity (LOH) score in the primary and recurrent ovarian cancer
The LOH score is a scale describing the genomic loss of heterozygosity status in the primary or recurrent tumor of an ovarian cancer patient. The score is determined by analyzing more than 3500 SNPs spaced at 1Mb intervals across the genome on the FoundationOne CDx test and extrapolating an LOH profile, excluding arm and chromosome-wide LOH segments. The score is summarized as the percentage of the genome with LOH regions.
Time frame: Through study completion, an average of 1 year]
Homologous recombination deficiency (HRD) status
The HRD status for primary or recurrent tumor in a patient is considered according to the LOH score and genomic mutation status of BRCA1 and BRCA2 genes in the sample. A sample with LOH≥16%，and/or with genomic mutation in BRCA1 or BRCA2 gene, is defined as HRD positive. Otherwise, a sample with LOH\<16% and wild type BRCA1/BRCA2 genes is defined as HRD negative.
Time frame: Through study completion, an average of 1 year
Progression-free survival
Progression-free survival in recruited patients
Time frame: From the beginning of the patient's onset, an average of 1 year
Overall survival
Overall survival in recruited patients
Time frame: From the beginning of the patient's onset, an average of 3 year
Xiaoxiang Chen, MD,PhD
CONTACT
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.